MOTS-c

1. Overview

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino acid mitochondrial-derived peptide (MDP) with the sequence MRWQEMGYIFYPRKLR and an approximate molecular weight of 2,174 Da [1]. It was discovered in 2015 by Changhan Lee and Pinchas Cohen at the University of Southern California Leonard Davis School of Gerontology, representing one of a class of biologically active peptides encoded by short open reading frames (sORFs) within mitochondrial DNA that had previously been thought to encode only 37 genes (13 proteins, 22 tRNAs, and 2 rRNAs) [1][18].

MOTS-c is encoded within the 12S ribosomal RNA gene (MT-RNR1) of the mitochondrial genome. Its discovery was paradigm-shifting because it demonstrated that mitochondria actively produce signaling peptides that regulate whole-body metabolism, functioning as what the discoverers termed a "mitochondrial hormone" or "mitokine" [18]. MOTS-c joins humanin and the SHLP1-6 family as mitochondrial-derived peptides that have rewritten our understanding of mitochondrial genetic output.

The peptide acts primarily by inhibiting the folate cycle (one-carbon metabolism), leading to accumulation of the endogenous metabolite AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), a potent activator of AMP-activated protein kinase (AMPK) [1]. Under conditions of metabolic stress, MOTS-c translocates from mitochondria to the nucleus, where it interacts with the NRF2 transcription factor and regulates genes containing antioxidant response elements (ARE) -- establishing it as the first known mitochondrial DNA-encoded factor capable of directly regulating nuclear gene expression [2][19]. Preclinical research has demonstrated beneficial effects in obesity, insulin resistance, exercise physiology, bone health, aging, and muscle homeostasis. Circulating MOTS-c levels decline with age, are reduced in obesity and type 2 diabetes, and increase with endurance exercise [1][3][6][7]. No human clinical trials have been completed as of March 2026.

Amino Acid Sequence

MRWQEMGYIFYPRKLR (16 residues)

Molecular Weight

~2174 Da

Encoded By

Mitochondrial 12S rRNA gene (MT-RNR1)

Discovery

Lee et al. 2015, Pinchas Cohen Lab, USC

Primary Mechanism

Folate cycle inhibition, AICAR accumulation, AMPK activation; nuclear translocation and gene regulation via NRF2/ARE

Key Target Tissues

Skeletal muscle, adipose tissue, bone

FDA Status

Not approved for any therapeutic use

Notable Variant

m.1382A>C (K14Q) -- Northeast Asian-specific, associated with altered longevity and diabetes risk

2. Mechanism of Action

2.1 Folate Cycle Inhibition and AMPK Activation

The primary intracellular mechanism of MOTS-c centers on regulation of one-carbon metabolism. MOTS-c inhibits the folate cycle and its coupled de novo purine biosynthesis pathway [1]. This inhibition causes cellular accumulation of AICAR, an intermediate in de novo purine synthesis that also functions as one of the most potent endogenous activators of AMPK [1][9].

AMPK (AMP-activated protein kinase) is a master metabolic sensor that, once activated, shifts cellular metabolism from anabolic (energy-storing) to catabolic (energy-consuming) programs. The MOTS-c/AICAR/AMPK axis results in:

• Enhanced glucose uptake in skeletal muscle, mediated by GLUT4 translocation [1][9]
• Increased fatty acid oxidation through phosphorylation and inhibition of acetyl-CoA carboxylase (ACC) [1][9]
• Suppression of lipogenesis and hepatic gluconeogenesis [1]
• Activation of PGC-1alpha, the master regulator of mitochondrial biogenesis, which in turn reciprocally promotes MOTS-c expression in a positive feedback loop [9]

In vitro studies confirmed that MOTS-c activates AMPK phosphorylation in a dose- and time-dependent manner across multiple cell types including HEK293 cells and C2C12 myocytes [1]. AMPK inhibition with compound C or siRNA knockdown blocks downstream MOTS-c effects, confirming AMPK dependence [2].

2.2 Nuclear Translocation and Gene Regulation

A landmark 2018 study by Kim et al. revealed that MOTS-c is not merely a cytoplasmic signaling molecule but can translocate to the nucleus under conditions of metabolic stress, including glucose restriction (0.5 g/L), serum deprivation (1% FBS), and oxidative stress (tert-butyl hydrogen peroxide, 100 uM) [2]. This nuclear translocation is AMPK-dependent: blocking AMPK with compound C or siRNA prevents MOTS-c accumulation in the nucleus [2].

Once in the nucleus, MOTS-c interacts with nuclear factor erythroid 2-related factor 2 (NRF2), a transcription factor that drives expression of genes containing antioxidant response elements (ARE) [2]. Chromatin immunoprecipitation (ChIP-qPCR) confirmed direct MOTS-c binding to ARE-containing promoter regions, and co-immunoprecipitation demonstrated MOTS-c/NRF2 complex formation [2]. RNA-seq analysis identified that MOTS-c regulates a broad range of stress-responsive nuclear genes including NQO1 and HO-1 [2].

This finding was profound because it established, for the first time, that a factor encoded by the mitochondrial genome can directly regulate nuclear gene expression -- providing evidence for bidirectional mitonuclear communication where both genomes produce factors that cross-regulate each other [2][19]. As Benayoun and Lee articulated, "cellular fitness requires the coevolved mitonuclear genomes to coordinate adaptive responses using gene-encoded factors that cross-regulate the opposite genome" [19].

2.3 CK2 Binding and Tissue-Specific Signaling

A 2024 mechanistic study by Kumagai et al. identified casein kinase 2 (CK2) as a direct binding partner and effector of MOTS-c [17]. MOTS-c directly binds to CK2 and activates it in cell-free systems, but with striking tissue specificity: systemic MOTS-c administration stimulates CK2 activity in skeletal muscle while suppressing it in adipose tissue [17]. CK2 activation in muscle mediates MOTS-c's effects on glucose uptake and muscle atrophy prevention, as CK2 inhibition abolished these effects [17]. The naturally occurring K14Q variant of MOTS-c showed reduced CK2 binding affinity, providing a molecular explanation for its diminished metabolic activity [17].

3. Researched Applications

3.1 Metabolic Regulation and Insulin Sensitivity

Evidence level: Preclinical (animal studies) with human correlative data

The discovery paper by Lee et al. (2015) demonstrated that MOTS-c treatment prevented high-fat diet-induced obesity in C57BL/6 mice, restored insulin sensitivity as measured by glucose tolerance tests, improved insulin-stimulated glucose disposal, and enhanced hepatic glucose control [1]. The peptide's primary metabolic target tissue was identified as skeletal muscle, where it enhanced glucose uptake and utilization [1].

Human clinical studies have confirmed that circulating MOTS-c levels are dysregulated in metabolic disease. Du et al. (2018) found that MOTS-c levels were significantly decreased in obese male children compared to healthy controls (472.61 vs. 561.64 ng/mL, P<0.01), with negative correlations to BMI, fasting insulin, HOMA-IR, and HbA1c [6]. Ramanjaneya et al. (2019) reported that serum MOTS-c was significantly lower in type 2 diabetes patients compared to healthy controls (P<0.007), with negative correlations to age, HbA1c, and glucose [7]. A separate study from the same group demonstrated that lipid infusion elevated plasma MOTS-c to 232% of basal levels in healthy controls and 349% in PCOS patients, while insulin attenuated this response [8].

In gestational diabetes mouse models, daily MOTS-c administration significantly alleviated hyperglycemia, improved insulin sensitivity and glucose tolerance, enhanced skeletal muscle glucose uptake, protected pancreatic beta-cells, and reduced offspring birth weight and mortality [16].

Yang et al. (2021) showed that MOTS-c and plasma levels were markedly reduced in high-fat diet-induced obese mice, that treadmill exercise restored these levels alongside improvements in AMPK phosphorylation, PGC-1alpha, and GLUT4, and that MOTS-c and PGC-1alpha reciprocally regulate each other through the AMPK pathway [9].

3.2 Exercise Mimetic Properties

Evidence level: Preclinical (animal studies) with human biomarker data

MOTS-c has been characterized as an exercise-induced mitokine that mimics several key adaptations of physical exercise. The landmark Reynolds et al. (2021) study in Nature Communications demonstrated in 10 young human males that exercise on a stationary bicycle significantly increased skeletal muscle MOTS-c (P=0.0098) and plasma MOTS-c (P=0.0011) [3]. In mice, MOTS-c treatment at 15 mg/kg enhanced treadmill performance in both young (12-week) and old (22-month) animals, with particularly striking effects in aged mice where total running distance improved (P=0.000002) [3].

Von Walden et al. (2021) showed that acute endurance exercise (45 minutes cycling at 70% VO2max) stimulated circulating mitochondrial-derived peptide levels in 30 healthy adults, while resistance exercise did not produce the same effect [10]. Hyatt (2022) found that 4-8 weeks of voluntary running in rodents increased skeletal muscle MOTS-c protein expression approximately 1.5-5-fold across multiple muscle types, with this elevation persisting through detraining periods of 4-6 weeks [13]. A single MOTS-c injection of 15 mg/kg enhanced untrained mice running performance by approximately 12-15% [13].

Domin et al. (2023) provided human correlative evidence showing that serum MOTS-c concentrations correlated positively with average power, maximal force during countermovement jumps, and leg muscle mass in 20 healthy adults, though notably not with peak VO2, suggesting that MOTS-c may preferentially influence muscle strength and power rather than aerobic capacity [15].

3.3 Aging and Longevity

Evidence level: Preclinical (animal studies) with human genetic association data

Endogenous MOTS-c levels decline with age in both mice and humans [1][20]. Late-life MOTS-c treatment in mice (beginning at 23.5 months, 3x/week) produced substantial improvements in multiple aging biomarkers: grip strength (P=0.000078), stride length (P=0.0038), walking performance (P=0.0428), blood glucose (P=0.0397), fat mass reduction, and lean mass increase (P=0.0003) [3]. MOTS-c also improved myoblast survival under metabolic stress and enhanced oxygen consumption rates in aged muscle cells [3].

The genetic association with human longevity was first reported by Fuku et al. (2015), who identified the m.1382A>C polymorphism within the MOTS-c-encoding region of mtDNA as specific to Northeast Asian populations and proposed it as a putative biological mechanism contributing to the exceptional longevity of Japanese centenarians [4]. This polymorphism produces a K14Q amino acid substitution in the MOTS-c peptide (lysine to glutamine at position 14).

The functional consequences of K14Q were elucidated by Zempo et al. (2021) in a meta-analysis of 27,527 individuals across three Japanese cohorts, which revealed that males (but not females) carrying the C allele exhibited higher type 2 diabetes prevalence, particularly among those in the lowest tertile of physical activity [5]. In vitro, K14Q-MOTS-c showed diminished insulin-sensitizing activity, and in HFD-fed male mice, the K14Q variant failed to produce the metabolic improvements seen with wild-type MOTS-c [5]. This kinesio-genomic interaction suggests that physical activity may compensate for the reduced efficacy of the K14Q variant.

Kumagai et al. (2022) further demonstrated that K14Q carriers had a higher proportion of MHC-IIx fast-twitch muscle fibers and greater peak leg torques, with the C allele most frequent in sprint/power athletes (6.5%) compared to endurance athletes (2.9%) and controls (5.1%) [14].

3.4 Skeletal Muscle Metabolism and Sarcopenia

Evidence level: Preclinical (animal studies) with human correlative data

Skeletal muscle is the primary target tissue for MOTS-c activity. The peptide enhances glucose uptake and oxidative metabolism in muscle through AMPK/GLUT4 signaling [1][9] and prevents muscle atrophy through CK2 activation [17]. Reynolds et al. (2021) demonstrated that MOTS-c treatment strengthened myoblast survival under metabolic stress conditions including glucose restriction and serum deprivation, with enhanced mitochondrial oxygen consumption rates [3].

The 2024 Kumagai et al. study revealed that male carriers of the K14Q variant exhibited higher risks for sarcopenia in an age- and physical activity-dependent manner, providing human genetic evidence linking MOTS-c function to muscle mass maintenance [17]. The finding that MOTS-c's muscle-protective effects are mediated through direct CK2 binding and activation -- and that the K14Q variant has reduced CK2 affinity -- offers a clear molecular explanation for the genetic association [17].

3.5 Osteoporosis and Bone Health

Evidence level: Preclinical (animal and in vitro studies)

Two studies have investigated MOTS-c in the context of bone health. Ming et al. (2016) demonstrated that MOTS-c at 5 mg/kg daily for 12 weeks significantly alleviated ovariectomy-induced bone loss in mice as measured by micro-CT [11]. The mechanism involved AMPK-dependent inhibition of RANKL-induced osteoclast differentiation, confirmed by the partial abrogation of MOTS-c's effects when the AMPK inhibitor compound C was administered [11].

Hu and Chen (2018) provided complementary evidence from an in vitro perspective, showing that MOTS-c remarkably stimulated calcified nodule formation in rat bone marrow mesenchymal stem cells and upregulated osteogenic markers (ALP, Bglap, Runx2) through activation of the TGF-beta/Smad signaling pathway [12]. TGF-beta1 knockdown reversed MOTS-c-promoted osteogenesis, confirming pathway specificity [12]. Together, these studies suggest MOTS-c may promote bone health through dual mechanisms: suppressing bone resorption (osteoclastogenesis) and promoting bone formation (osteoblast differentiation).

4. Clinical Evidence Summary

5. Dosing in Research

The following table summarizes doses used in published preclinical research studies. These are not therapeutic recommendations. MOTS-c is not approved for human use, and no human dosing studies have been published. All published animal studies have used intraperitoneal injection as the route of administration.

6. Pharmacokinetics

Current State of Knowledge

The pharmacokinetics of MOTS-c remain poorly characterized compared to most investigational peptides, as no formal PK studies have been published. All published animal studies have used intraperitoneal (IP) injection, and no human pharmacokinetic data exist. The following represents the best available information from endogenous level measurements and indirect evidence.

Endogenous Circulating Levels

Endogenous MOTS-c is detectable in human plasma in the low ng/mL range. Du et al. (2018) measured baseline plasma MOTS-c in healthy children at approximately 561.64 ng/mL (by ELISA), with significantly lower levels in obese children (472.61 ng/mL) [6]. Ramanjaneya et al. (2019) confirmed that MOTS-c levels decline with age and are reduced in type 2 diabetes (P less than 0.007 vs. controls) [7]. Lipid infusion elevated plasma MOTS-c to 232-349% of basal levels within hours, while insulin suppressed this response [8]. These observations suggest dynamic regulation of endogenous MOTS-c secretion but do not define exogenous PK parameters.

Exercise-Induced Kinetics

Reynolds et al. (2021) demonstrated that acute exercise on a stationary bicycle significantly increased both skeletal muscle MOTS-c (P=0.0098) and plasma MOTS-c (P=0.0011) in young human males [3]. Von Walden et al. (2021) showed that 45 minutes of cycling at 70% VO2max stimulated circulating MOTS-c, while resistance exercise did not [10]. Hyatt (2022) found that chronic voluntary running increased skeletal muscle MOTS-c 1.5-5-fold, and this elevation persisted through 4-6 weeks of detraining, suggesting intracellular MOTS-c has a relatively long functional half-life within muscle tissue [13].

Estimated PK Parameters

Based on the available evidence, the following PK characteristics can be inferred:

• Route of administration: All animal efficacy studies used IP injection. No IV, SC, or oral PK data exist. The oral bioavailability of MOTS-c is expected to be negligible due to gastrointestinal proteolysis of the 16-amino acid peptide.
• Molecular weight: Approximately 2,174 Da, which is below the typical renal filtration threshold (~60,000 Da) but within the range of peptides susceptible to rapid proteolytic degradation.
• Tissue distribution: MOTS-c accumulates preferentially in skeletal muscle, the primary target tissue [1][3]. Under metabolic stress, it translocates to the nucleus [2].
• Metabolism: No specific metabolic pathways or degradation enzymes have been identified for exogenous MOTS-c. As a 16-amino acid peptide, it is presumably subject to degradation by serum and tissue peptidases.
• Functional duration: Single IP injections of 15 mg/kg enhanced mouse running performance acutely [13], while three-times-weekly dosing at 15 mg/kg sustained benefits over weeks to months in aged mice [3], suggesting the effective functional duration extends beyond the expected plasma half-life through tissue accumulation or downstream signaling persistence.

PK Limitations and Research Needs

The absence of formal pharmacokinetic data is a critical gap in MOTS-c translational research. Priorities include determining plasma half-life after IV/SC administration, defining the volume of distribution, characterizing renal vs. hepatic clearance, establishing bioavailability by different routes, and determining dose-exposure-response relationships in humans.

7. Dose-Response Relationships

Metabolic Effects (Animal Studies)

The dose-response for MOTS-c's metabolic effects has been characterized across several studies:

• 5 mg/kg IP daily (7-14 days): The original Lee et al. (2015) study demonstrated prevention of HFD-induced obesity, improved glucose tolerance, and enhanced insulin sensitivity at this dose [1]. This was also the dose used by Ming et al. (2016) for bone protection over 12 weeks [11].
• 15 mg/kg IP daily (2 weeks): Reynolds et al. (2021) used this higher dose in young mice and demonstrated significant improvements in treadmill running performance [3].
• 15 mg/kg IP single injection: Hyatt (2022) showed a single acute dose enhanced untrained mice running distance by approximately 12-15% [13].
• 15 mg/kg IP 3x/week (chronic, late-life): Reynolds et al. (2021) initiated this regimen in 23.5-month-old mice and observed improvements in grip strength (P=0.000078), stride length (P=0.0038), walking performance (P=0.0428), blood glucose (P=0.0397), and body composition [3].

Exercise Interactions

MOTS-c and exercise appear to have synergistic or additive effects. Yang et al. (2021) demonstrated that MOTS-c interacted synergistically with treadmill exercise intervention to activate AMPK, upregulate PGC-1alpha and GLUT4, and improve insulin resistance more effectively than either intervention alone [9]. The Zempo et al. (2021) meta-analysis revealed a kinesio-genomic interaction: the metabolic disadvantage of the K14Q variant was most pronounced in the lowest physical activity tertile (OR for T2D: 1.43 in the least active males), suggesting that exercise can compensate for reduced MOTS-c function [5].

Dose-Response by Sex

A consistent finding across studies is sex-differential responsiveness to MOTS-c. Zempo et al. (2021) found that the K14Q variant increased T2D prevalence in males but not females [5]. In HFD-fed mice, K14Q-MOTS-c failed to produce metabolic improvements in males but was not tested in females [5]. Kumagai et al. (2024) confirmed that male K14Q carriers had higher sarcopenia and T2D risk in an age- and activity-dependent manner [17]. This dimorphism suggests that dose-response parameters may differ by sex, though this has not been systematically studied.

AICAR Accumulation Kinetics

The mechanism linking MOTS-c dose to AMPK activation involves dose- and time-dependent inhibition of the folate cycle and accumulation of AICAR [1]. Lee et al. (2015) demonstrated in HEK293 cells that MOTS-c treatment produced measurable AICAR accumulation within hours and AMPK phosphorylation in a concentration-dependent manner [1]. The AMPK activation threshold and the dose-response curve for folate cycle inhibition in vivo remain to be precisely defined.

8. Comparative Effectiveness

MOTS-c vs. Metformin

Metformin, the first-line oral antidiabetic drug, shares several mechanistic parallels with MOTS-c, as both activate AMPK and improve insulin sensitivity. Key comparisons:

• AMPK activation mechanism: Metformin inhibits mitochondrial complex I, increasing the AMP/ATP ratio and activating AMPK indirectly. MOTS-c inhibits the folate cycle, accumulates AICAR, and activates AMPK through a distinct mechanism [1]. The different entry points into AMPK activation suggest potential complementary effects, though this has not been tested.
• Metabolic outcomes (preclinical): Both prevent HFD-induced obesity and improve insulin sensitivity in mice. MOTS-c at 5 mg/kg/day produced effects comparable to metformin at 200-300 mg/kg/day in mouse studies, though direct head-to-head comparisons are lacking.
• Exercise mimetic properties: MOTS-c more closely mimics exercise adaptations than metformin. MOTS-c is exercise-induced and enhances exercise performance [3][13], whereas metformin may actually blunt some exercise training adaptations (muscle mitochondrial biogenesis) in certain populations.
• Route: Metformin is orally bioavailable (50-60%) and well-tolerated. MOTS-c requires parenteral administration and has no human dosing data.
• Evidence base: Metformin has been used in over 150 million patients worldwide with over 60 years of clinical data. MOTS-c has zero human clinical trials.
• Longevity: Both are under investigation as geroprotective agents. The TAME (Targeting Aging with Metformin) trial is underway for metformin. MOTS-c extends healthspan in aged mice but has no human aging data.

MOTS-c vs. AICAR (Direct AMPK Activator)

AICAR is the pharmacological AMPK activator that MOTS-c causes to accumulate endogenously:

• Mechanism: AICAR directly mimics AMP and activates AMPK. MOTS-c causes endogenous AICAR accumulation through folate cycle inhibition, producing a more physiological activation pattern [1].
• Exercise mimetic: AICAR has been shown to enhance endurance in sedentary mice (Narkar et al. 2008, Cell). MOTS-c similarly enhances running performance in both young and aged mice [3][13].
• Specificity: Direct AICAR administration activates AMPK systemically and can have off-target effects on purine metabolism. MOTS-c appears to have preferential effects on skeletal muscle, mediated in part through direct CK2 binding [17].
• WADA status: AICAR (acadesine) is on the WADA prohibited list. MOTS-c is not specifically listed.

MOTS-c vs. Exercise

MOTS-c has been characterized as an "exercise mimetic," and the comparison is particularly relevant:

• Shared pathways: Both activate AMPK, upregulate PGC-1alpha, enhance GLUT4 translocation, and increase fatty acid oxidation [1][9].
• Muscle effects: Both increase muscle carnosine content (indirectly for exercise) and improve muscle function. Exercise increases endogenous MOTS-c by 1.5-5-fold [3][13].
• Magnitude of effect: A single MOTS-c injection improved running performance by 12-15% in untrained mice [13]. In aged mice, chronic MOTS-c improved grip strength with P=0.000078 and running distance with P=0.000002 [3].
• Breadth of effects: Exercise produces cardiovascular, skeletal, neurological, psychological, and social benefits that no pharmacological agent can fully replicate. MOTS-c appears to capture primarily the metabolic and musculoskeletal components.
• K14Q interaction: Physical activity compensates for the reduced efficacy of the K14Q variant, suggesting that exercise and MOTS-c engage overlapping but not identical pathways [5].

MOTS-c vs. Other Mitochondrial-Derived Peptides

Humanin: The founding MDP, encoded in the 16S rRNA gene. Humanin acts primarily through the CNTFR/WSX-1/gp130 receptor complex and BAX antagonism, focusing on cytoprotection and neuroprotection. MOTS-c acts through AMPK/folate cycle/CK2 pathways, focusing on metabolism and muscle function. Humanin and MOTS-c have distinct and largely non-overlapping mechanisms, suggesting they may represent a complementary MDP signaling system for different biological challenges (cellular survival vs. metabolic regulation).

SHLP1-6: Small humanin-like peptides, also encoded in the 16S rRNA gene. SHLP2 and SHLP6 are the best characterized, with anti-apoptotic and pro-apoptotic activities respectively. Their mechanisms and tissue specificity are distinct from MOTS-c.

Centenarian Variant Data (K14Q)

The m.1382A>C polymorphism producing the K14Q MOTS-c variant is specific to Northeast Asian populations and has been extensively characterized:

• Frequency: Approximately 5% of Japanese population; 6.5% of sprint/power athletes; 2.9% of endurance athletes; 5.1% of general controls [4][14].
• Longevity association: Originally proposed as contributing to exceptional longevity in Japanese populations [4], but subsequent functional studies revealed a more complex picture.
• Diabetes risk: Meta-analysis of 27,527 individuals showed increased T2D prevalence in male K14Q carriers in the lowest physical activity tertile (OR approximately 1.43) [5].
• Muscle fiber composition: K14Q carriers have higher MHC-IIx (fast-twitch) fiber proportion and greater peak leg torques, favoring power/sprint athletics [14].
• Molecular mechanism: K14Q reduces CK2 binding affinity, diminishing MOTS-c's ability to activate CK2 in skeletal muscle and thereby reducing glucose uptake and muscle-protective effects [17].
• Sarcopenia risk: Male K14Q carriers show higher sarcopenia risk in an age-dependent manner [17].
• Interpretation: The K14Q variant appears to shift the MOTS-c phenotype from metabolic/endurance toward power/fast-twitch characteristics, with a metabolic cost (increased diabetes and sarcopenia risk) that can be partially offset by physical activity.

9. Safety and Side Effects

Preclinical Safety Profile

MOTS-c is an endogenous peptide naturally produced by human mitochondria and present in circulating plasma at concentrations of approximately 400-600 ng/mL (measured by ELISA), which provides a theoretical safety advantage over synthetic compounds [1][6][18]. In published animal studies spanning durations from single injection to 12 weeks of daily administration (5-15 mg/kg IP), no adverse effects have been reported across any study [1][3][11][13].

Quantitative Preclinical Safety Data

• Acute toxicity: Single doses of 15 mg/kg IP in mice produced no adverse events [13]. No LD50 has been determined, and no dose-limiting toxicity has been identified in any published study.
• Subchronic exposure (2 weeks): 15 mg/kg daily IP in young mice (Reynolds et al. 2021) -- no adverse effects; improved treadmill performance [3].
• Chronic exposure (12 weeks): 5 mg/kg daily IP in ovariectomized mice (Ming et al. 2016) -- no adverse effects; preserved bone density [11].
• Late-life chronic exposure: 15 mg/kg 3x/week IP starting at 23.5 months of age in mice (Reynolds et al. 2021) -- no adverse effects; improved grip strength, stride length, body composition, and glucose homeostasis [3].
• Body weight effects: MOTS-c prevents HFD-induced obesity (significant weight reduction vs. HFD controls) but does not cause pathological weight loss in lean animals [1].
• Organ toxicity: No studies have reported histopathological examination of major organs following MOTS-c treatment, which represents a gap in the preclinical safety database.
• Reproductive safety: MOTS-c administered during pregnancy in a GDM mouse model reduced offspring birth weight and mortality and improved maternal metabolic parameters without reported maternal or fetal toxicity [16], though this was a disease model study rather than a formal reproductive toxicity assessment.
• Hematological safety: No hematological parameters have been reported in MOTS-c animal studies.

Unknown Risks and Considerations

Despite the favorable preclinical profile, significant safety unknowns remain:

• No human clinical trials: The safety, pharmacokinetics, and pharmacodynamics of exogenous MOTS-c in humans have not been systematically evaluated. Circulating MOTS-c levels in humans are in the ng/mL range [6], and the consequences of supraphysiological dosing are unknown.
• Long-term AMPK activation: Chronic systemic AMPK activation could theoretically affect cardiac function, reproductive biology, and tissue homeostasis in ways not captured by existing short-term animal studies.
• Folate cycle disruption: Because MOTS-c acts by inhibiting the folate cycle and one-carbon metabolism, long-term use could theoretically impact purine synthesis, DNA methylation, and homocysteine levels. These effects have not been characterized at therapeutic doses.
• Sex-specific effects: The Zempo et al. (2021) study revealed that MOTS-c's metabolic effects may be sex-dependent, with male mice showing greater responsiveness than females [5]. Safety implications of this dimorphism are unstudied.
• K14Q variant interactions: Approximately 5% of Northeast Asian populations carry the K14Q variant, which may alter the response to exogenous wild-type MOTS-c administration [5][14]. Whether variant carriers require different dosing considerations is unknown.
• Drug interactions: No studies have examined interactions between exogenous MOTS-c and pharmaceutical agents including metformin (which also activates AMPK), insulin, or other metabolic medications.
• Reproductive and developmental safety: No data exists on use during pregnancy, lactation, or in pediatric populations. The gestational diabetes study administered MOTS-c during mouse pregnancy with beneficial offspring outcomes [16], but this cannot be extrapolated to human safety.

Regulatory Status

MOTS-c is not approved by the FDA or any other regulatory authority for human therapeutic use. No Investigational New Drug (IND) applications are on public record. As a research peptide, it is available from chemical suppliers for in vitro and animal research purposes only. No human clinical trials of MOTS-c itself are registered on ClinicalTrials.gov as of March 2026. However, CB4211, a MOTS-c analog developed by CohBar, completed a Phase 1a/1b trial in 2021 in 20 obese participants with NAFLD, though the program has not advanced further.

Recent 2025 research has continued to expand MOTS-c's preclinical evidence base. A study published in Experimental and Molecular Medicine (2025) demonstrated that MOTS-c prevents pancreatic islet cell senescence by modulating nuclear gene expression and metabolites involved in beta-cell aging, suggesting potential applications in preserving beta-cell function and delaying diabetes onset. A separate 2025 study in Frontiers in Physiology showed that MOTS-c restores mitochondrial respiration in the type 2 diabetic heart, providing evidence for cardioprotective effects. Additionally, a prospective human observational study found that circulating MOTS-c levels are significantly reduced in patients who develop acute lung injury following cardiopulmonary bypass, further supporting MOTS-c as a biomarker of mitochondrial stress and tissue protection.

10. Related Peptides

See also: Humanin, SS-31 (Elamipretide), BPC-157, Epitalon

11. References

1. [1] Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. DOI PubMed
2. [2] Kim KH, Son JM, Benayoun BA, Lee C. (2018). The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism. DOI PubMed
3. [3] Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. DOI PubMed
4. [4] Fuku N, Pareja-Galeano H, Zempo H, Alis R, Arai Y, Lucia A, Hirose N. (2015). The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity?. Aging Cell. DOI PubMed
5. [5] Zempo H, Kim SJ, Fuku N, Nishida Y, Higaki Y, Wan J, Kumagai H, Seto H, Tanaka K, Lucia A, Alis R, Pareja-Galeano H, Arai Y, Hirose N, Lee C. (2021). A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging. DOI PubMed
6. [6] Du C, Zhang C, Wu W, Liang Y, Wang A, Wu S, Zhao Y, Hou L, Ning Q, Luo X. (2018). Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance. Pediatric Diabetes. DOI PubMed
7. [7] Ramanjaneya M, Bettahi I, Jerobin J, Chandra P, Abi Khalil C, Skarulis M, Atkin SL, Abou-Samra AB. (2019). Mitochondrial-derived peptides are down regulated in diabetes subjects. Frontiers in Endocrinology. DOI PubMed
8. [8] Ramanjaneya M, Jerobin J, Bettahi I, Bensila M, Abi Khalil C, Skarulis M, Atkin SL, Abou-Samra AB. (2019). Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in PCOS and healthy subjects. Clinical Endocrinology. DOI PubMed
9. [9] Yang B, Yu Q, Chang B, Guo Q, Xu S, Yi X, Cao S. (2021). MOTS-c interacts synergistically with exercise intervention to regulate PGC-1alpha expression, attenuate insulin resistance and enhance glucose metabolism in mice via AMPK signaling pathway. Biochimica et Biophysica Acta - Molecular Basis of Disease. DOI PubMed
10. [10] von Walden F, Fernandez-Gonzalo R, Norrbom J, Emanuelsson EB, Figueiredo VC, Gidlund EK, Norrbrand L, Flack D, Perrmann T, Brioche T, Chao T, Cohen P, Cheng T, Lundberg TR. (2021). Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. Journal of Applied Physiology. DOI PubMed
11. [11] Ming W, Lu G, Xin S, Huanyu L, Yinghao J, Xiaoying L, Chengming X, Banjun R, Li W, Zifan L. (2016). Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation. Biochemical and Biophysical Research Communications. DOI PubMed
12. [12] Hu BT, Chen WZ. (2018). MOTS-c improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-beta/Smad pathway. European Review for Medical and Pharmacological Sciences. DOI PubMed
13. [13] Hyatt JK. (2022). MOTS-c increases in skeletal muscle following long-term physical activity and improves acute exercise performance after a single injection in mice. Physiological Reports. DOI PubMed
14. [14] Kumagai H, Coelho AR, Wan J, Mehta HH, Yen K, Huang A, Zempo H, Fuku N, Maeda S, Oliveira PJ, Cohen P, Lee C. (2022). The MOTS-c K14Q polymorphism in the mtDNA is associated with muscle fiber composition and sprint/power athletic status. Biochimica et Biophysica Acta - General Subjects. DOI PubMed
15. [15] Domin R, Pytka M, Niziński J, Żołyński M, Zybek-Kocik A, Wrotkowska E, Ziętkiewicz S, Ruchała M, Guzik P, Korybalska K. (2023). MOTS-c serum concentration positively correlates with lower-body muscle strength and force during countermovement jumps. International Journal of Molecular Sciences. DOI PubMed
16. [16] Yin Y, Pan Y, He J, Zhong H, Wu Y, Ji C, Liu L, Cui X. (2022). MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus. Pharmacological Research. DOI PubMed
17. [17] Kumagai H, Natsume T, Kim SJ, Tobina T, Miyamoto-Mikami E, Shiose K, Ichinoseki-Sekine N, Kakigi R, Tsuzuki T, Miller B, Wan J, Yen K, Mehta HH, Kumagai ME, Sato K, Naito H, Fuku N, Cohen P, Lee C. (2024). MOTS-c modulates skeletal muscle function by directly binding and activating CK2. iScience. DOI PubMed
18. [18] Lee C, Kim KH, Cohen P. (2016). MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radical Biology and Medicine. DOI PubMed
19. [19] Benayoun BA, Lee C. (2019). MOTS-c: A mitochondrial-encoded regulator of the nucleus. BioEssays. DOI PubMed
20. [20] Mohtashami Z, Singh MK, Salimiaghdam N, Ozgul M, Kenney MC. (2022). MOTS-c, the most recent mitochondrial-derived peptide in human aging and age-related diseases. International Journal of Molecular Sciences. DOI PubMed
21. [21] Zheng Y, Wei Z, Wang T. (2023). MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology. DOI PubMed
22. [22] Parseh S, Shakerian S, Ghasemi A, Salehi M. (2024). An 8-week study on high and moderate-intensity interval exercises on mitochondrial MOTS-c in male diabetic sand rats. Diabetes Research and Clinical Practice. DOI PubMed